Sol Gel Technologies (NASDAQ:SLGL) Issues Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Sol Gel Technologies (NASDAQ:SLGL) posted its earnings results on Tuesday. The company reported ($0.26) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.32) by $0.06, Fidelity Earnings reports. Sol Gel Technologies had a negative net margin of 300.12% and a negative return on equity of 65.00%. The firm had revenue of $7.79 million during the quarter, compared to the consensus estimate of $7.00 million.

Shares of NASDAQ:SLGL traded up $0.02 during trading on Friday, hitting $8.25. The company’s stock had a trading volume of 8,575 shares, compared to its average volume of 26,681. The business has a 50 day moving average price of $9.54 and a two-hundred day moving average price of $7.97. The company has a market capitalization of $157.06 million, a PE ratio of -4.58 and a beta of 0.51. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.29 and a current ratio of 8.29. Sol Gel Technologies has a fifty-two week low of $5.41 and a fifty-two week high of $11.36.

SLGL has been the subject of several research reports. ValuEngine downgraded shares of Sol Gel Technologies from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Zacks Investment Research downgraded shares of Sol Gel Technologies from a “buy” rating to a “hold” rating in a report on Friday, July 19th. Finally, HC Wainwright lifted their target price on shares of Sol Gel Technologies from $21.00 to $23.00 and gave the company a “buy” rating in a report on Tuesday, July 9th.



About Sol Gel Technologies

Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea.

Read More: Average Daily Trade Volume Explained

Earnings History for Sol Gel Technologies (NASDAQ:SLGL)

Receive News & Ratings for Sol Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.